# PDUFA dates explained: what an FDA goal date is and how to track it

> A PDUFA date is the FDA's target date to act on a drug or biologic application. Learn how it is calculated, why it can move, and what happens on the day.

Source: https://www.quantisnow.com/guides/pdufa-dates-explained
Section: Guides / Biotech and FDA
Last updated: 2026-10-25

## Key takeaways

- A PDUFA date is the target date by which the FDA aims to act on a new drug or biologic application, set under performance goals negotiated in the Prescription Drug User Fee Act.
- For a new molecular entity or original BLA, the PDUFA date is about 12 months after submission under standard review or about 8 months under priority review.
- The FDA does not generally publish PDUFA dates; investors learn them from the company, usually in the press release announcing that the application was accepted for review.
- A major amendment can push the PDUFA date back by three months, and the FDA can act before the goal date or, occasionally, miss it.
- On or before the PDUFA date the FDA issues either an approval or a complete response letter, so the date is one of the biggest scheduled catalysts for a small biotech.

A PDUFA date is the target date by which the US Food and Drug Administration aims to complete its review of a new drug or biologic application and take action, either approving it or issuing a complete response letter. The name comes from the Prescription Drug User Fee Act, the law under which drug companies pay user fees and the FDA commits to review timelines. For a small biotech with one product, the PDUFA date can be the single most important scheduled event in its history.

## What is a PDUFA date?

A PDUFA date (also called a PDUFA goal date, target action date or FDA action date) is the deadline the FDA sets for itself to act on a specific application under its PDUFA performance goals. It is a goal, not a statutory deadline: the FDA commits to meeting it for 90% of applications in a category, and in practice it meets the large majority of them.

The FDA's possible actions on that date are:

- **Approval**, with an approved label (prescribing information) that defines the indication, dosing and warnings.
- **Complete response letter (CRL)**, meaning the FDA cannot approve the application as submitted and lists the deficiencies.

There is no "partial" action in the formal sense, but an approval with a narrower indication, a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) can feel like a partial win to the market.

The broader process is covered in the [FDA approval process guide](https://www.quantisnow.com/guides/fda-approval-process).

## How is the PDUFA date calculated?

The goal date depends on the type of application and whether it receives priority or standard review:

| Application | Standard review | Priority review |
|---|---|---|
| New molecular entity NDA or original BLA | 10 months after the 60-day filing date (about 12 months from submission) | 6 months after the 60-day filing date (about 8 months from submission) |
| Non-NME original NDA | 10 months from receipt | 6 months from receipt |
| Efficacy supplement (new indication for an approved drug) | 10 months from receipt | 6 months from receipt |
| Class 1 resubmission after a CRL | 2 months from receipt | 2 months from receipt |
| Class 2 resubmission after a CRL | 6 months from receipt | 6 months from receipt |

These goals come from the PDUFA performance goals letter, which the FDA publishes for each five-year reauthorization; the current version is available on the [FDA's PDUFA page](https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments).

For new molecular entities and original biologics, the FDA uses a "Program" review model that includes a 60-day filing period before the 10-month or 6-month review clock starts. That is why the total time is 12 or 8 months.

## How do investors find out the PDUFA date?

The FDA generally does not publish upcoming PDUFA dates for pending applications. The company learns its date when the FDA files the application (within 60 days of submission) and typically discloses it in a press release such as "FDA accepts NDA for review and grants priority review; PDUFA target action date of September 16." Many companies also file an 8-K or mention the date in their 10-Q and investor presentations.

Because the dates come from companies, they vary in precision. Some companies give an exact date, others only a quarter or month. Independent PDUFA calendars aggregate these company disclosures.

## Why does a PDUFA date move?

### Major amendments: a three-month extension

If the sponsor submits a major amendment during review, for example substantial new clinical or manufacturing data, often at the FDA's request, the FDA can extend the goal date by three months. Only one such extension is allowed per review cycle. Companies usually announce these extensions, and the market reaction depends on whether the FDA is signaling a fixable gap or a deeper problem.

### Early action

The FDA can act before the goal date. Early approvals happen, particularly for priority applications, but investors should not assume an early decision.

### Missed goal dates

Occasionally the FDA misses a PDUFA date, most often because it could not complete a required facility inspection (for example at an overseas manufacturing site) or because of a heavy review workload. The company typically announces that the date passed without action and that review is ongoing.

### Weekends and holidays

When a goal date falls on a weekend or federal holiday, the FDA often acts on the preceding business day, though it is not bound to.

## What happens around the PDUFA date?

Key milestones in a typical review cycle:

| Milestone | Approximate timing (NME, standard review) | What it can reveal |
|---|---|---|
| Submission | Month 0 | Company press release |
| Filing decision | Day 60 | Acceptance or refuse-to-file letter; PDUFA date disclosed |
| Day 74 letter | Day 74 | Whether the FDA has flagged review issues so far; whether an AdComm is planned |
| Mid-cycle communication | Around month 7 | Status of the review, possible deficiencies |
| Advisory committee | Varies, if held | Outside experts vote on benefit and risk |
| Late-cycle meeting | About 3 months before the goal date | Remaining issues, labeling discussions |
| Label negotiation | Final weeks | Signs that approval is likely |
| PDUFA date | Month 12 | Approval or CRL |

Companies sometimes disclose that "labeling discussions are underway," which investors generally treat as a constructive sign, though it is not a guarantee.

## Trading dynamics: PDUFA as a binary event

A PDUFA date is often called a binary event because the outcome is largely yes or no and can move a small-cap stock by a large percentage in either direction. Common patterns observed by traders:

- **Run-up.** Speculative buying in the weeks before a widely watched date.
- **Elevated implied volatility.** Options on the stock price in a large expected move, then implied volatility typically collapses once the decision is known. See [options chain basics](https://www.quantisnow.com/guides/options-chain-basics).
- **Sell the news.** Even an approval can be followed by a decline if expectations were fully priced in or the label is narrower than hoped. The [trading news catalysts guide](https://www.quantisnow.com/guides/trading-news-catalysts) covers this pattern.
- **Timing.** FDA decisions are often announced by the company after the close or before the open, and sometimes during market hours, which can lead to a trading halt pending news.
- **Financing.** Approved companies often raise capital soon after approval to fund a launch, which can add dilution.

None of these patterns are reliable enough to predict an individual outcome.

## Worked example: Acme Bio (ticker ACMB)

Hypothetical Acme Bio submits an original BLA on January 15 for a new biologic.

| Date | Event |
|---|---|
| January 15 | BLA submitted |
| March 16 (day 60) | FDA files the BLA and grants priority review; Acme announces a PDUFA date of September 16 (6 months after the filing date, about 8 months after submission) |
| Late March | Day 74 letter notes no AdComm is currently planned |
| June | FDA asks for additional stability data; Acme submits it, and the FDA classifies it as a major amendment |
| June | Acme announces the PDUFA date is extended by three months to December 16 |
| Early December | Acme says labeling discussions are underway |
| December 15 | FDA approves the BLA one day before the goal date |

The key information for investors arrived in company announcements at day 60, at the extension, and on the action date itself.

## How to track PDUFA dates and FDA decisions on Quantisnow

- The [FDA news feed](https://www.quantisnow.com/news/fda) streams acceptance announcements (which carry PDUFA dates), extensions, approvals and CRLs as they publish.
- [Top FDA approvals](https://www.quantisnow.com/top/fda-approvals) shows the latest approval news across companies.
- Add biotech names using [following tickers](https://www.quantisnow.com/docs/following-tickers) and turn on [alerts](https://www.quantisnow.com/docs/alerts) so an after-hours decision reaches you immediately.
- Company pages follow the pattern /company/AAPL and collect each company's FDA-related releases and filings.

## FAQ

### What does PDUFA stand for?

PDUFA stands for the Prescription Drug User Fee Act, first passed in 1992 and reauthorized every five years. Under it, companies pay fees and the FDA commits to review timelines, which produce each application's PDUFA goal date.

### Does the FDA always decide on the PDUFA date?

No. The FDA meets the large majority of its PDUFA goals, but it can act early, extend the date by three months after a major amendment, or occasionally miss it, often because of an outstanding facility inspection.

### Where can I find a company's PDUFA date?

The FDA generally does not publish pending PDUFA dates. Companies disclose them, usually in the press release announcing the FDA has accepted the application for review, and in later SEC filings and presentations.

### What happens if the FDA misses a PDUFA date?

The application remains under review and the FDA acts later. The company typically issues a statement, and the delay is often tied to an incomplete inspection or other review workload rather than a decision against approval.

### Is a PDUFA date the same as an approval date?

No. The PDUFA date is the FDA's target date to take action. The action can be an approval or a complete response letter, and it can come before the goal date.